DCM
LAB icon

Delpha Capital Management’s Standard BioTools LAB Stock Holding History

Delpha Capital Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-602
Closed -$4K – 704
2017
Q4 		$4K Buy
+602
New +$3.29K ﹤0.01% 1354

Other funds holding LAB

LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Delpha Capital Management's LAB Position: Q1 2018 in Review

Delpha Capital Management sold out of Standard BioTools (LAB) in Q1 2018, closing a stake of 602 shares — an estimated $4K sold.

Delpha Capital Management first reported a position in LAB in Q4 2017 and held it in 1 quarter. The position peaked at $4K in Q4 2017. 84 funds tracked by Wall St. Rank hold LAB as of Q1 2018.

  • Delpha Capital Management reported no remaining Standard BioTools position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 602 Standard BioTools shares in Q1 2018, an estimated $4K.
  • Delpha Capital Management first reported a position in Standard BioTools in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Standard BioTools position peaked at $4K in Q4 2017.
  • 84 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.